california tirzepatide Get in | Personalized GLP-1 Therapy Tirzepatide | Wellness Center in

The exception: in March 2024, the FDA approved a supplemental indication for semaglutide 2.4 mg (Wegovy) to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight (SELECT trial, Lincoff et al., New England Journal of Medicine 2023)

This is why we see growing interest in Mycotherapy (medicinal mushrooms) to support gut health and hormonal homeostasis in GLP-1 patientshelping to balance the system while naturally mitigating common digestive side effects

They can evaluate whether your schedule is medically appropriate and suggest alternatives if your situation genuinely requires different timing

As diabetes research continues to evolve, semaglutide is poised to play a pivotal role in future management strategies

he duration of the program may vary based on individual goals and progress